qi


April 6, 2009  
Share |

Moleac Publishes Data Supporting NeuroAID for Stroke Recovery

Moleac, a Singapore-based biopharmaceutical company that develops new medicines based on traditional medicines, has published data demonstrating excellent tolerability for NeuroAID, as well as efficacy in improving neurological recovery after stroke. This data was published in the peer-reviewed journal Stroke in its March 2009 print edition.

Moleac was one of the companies featured in the top story for June 2008 of Acupuncture Today, which discussed the current trend among Chinese herbal companies to emulate the Western pharmaceutical model ("When East Becomes West").

The authors (Chen, et al.) analyzed pooled data from previously unpublished trials of NeuroAID on a total of 605 patients. These studies were randomized, double-blinded, controlled trials, where stroke patients received NeuroAID or a matched traditional medicine as a control, for a month. Treatment was initiated an average of two months after stroke. These studies were conducted in 1999 and 2000 in China.

The efficacy results showed significant improvements over the control group, in terms of regaining independence and recovering from motor neurological deficits.

The safety results showed no severe adverse effects, with only two cases of nausea and vomiting. The authors make a call for further clinical trials to be conducted at the early stage of stroke to evaluate the efficacy of NeuroAID when initiated immediately after the stroke onset. One such trial is ongoing and conducted by the CHIMES society in Asia.

Mr David Picard, CEO of Moleac said, "We are very happy to see this data published in Stroke. It is a strong validation of the quality of our research. It also shows the value of Moleac's approach: looking at alternative sources of innovations in traditional medicine. We have come up with Neuroaid, which addresses the gap in stroke treatment and is an answer to unmet medical needs for patients and strokologists."

 

Join the conversation
Comments are encouraged, but you must follow our User Agreement
Keep it civil and stay on topic. No profanity, vulgar, racist or hateful comments or personal attacks. Anyone who chooses to exercise poor judgement will be blocked. By posting your comment, you agree to allow MPA Media the right to republish your name and comment in additional MPA Media publications without any notification or payment.
comments powered by Disqus

AT News Update
e-mail newsletter Subscribe Today

AT Deals & Events
e-mail newsletter Subscribe Today